Published in Br J Cancer on March 19, 2015
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Chronic illness management: what is the role of primary care?. Ann Intern Med (2003) 3.60
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol (2011) 3.32
Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer (2009) 3.27
Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer (2011) 3.23
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer (2012) 2.24
Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol (2013) 2.16
Prostate cancer and health-related quality of life: a review of the literature. Psychooncology (2002) 1.85
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int (2009) 1.62
Primary care oncology: essential if high quality cancer care is to be achieved for all. Fam Pract (2002) 1.59
General practictioners' management of cancer in England: secondary analysis of data from the National Survey of NHS Patients-Cancer. Eur J Cancer Care (Engl) (2005) 1.57
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
New pathways of care for cancer survivors: adding the numbers. Br J Cancer (2011) 1.31
Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int (2010) 1.26
The economic burden of prostate cancer. BJU Int (2011) 1.23
The economic consequences of prostate and bladder cancer in the UK. BJU Int (2005) 1.21
A qualitative study of unmet needs and interactions with primary care among cancer survivors. Br J Cancer (2011) 1.08
Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol (2011) 1.05
A person-time analysis of hospital activity among cancer survivors in England. Br J Cancer (2011) 1.05
Experiences of follow-up after treatment in patients with prostate cancer: a qualitative study. BJU Int (2010) 1.02
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess (2007) 1.02
Bone-targeting radiopharmaceuticals including radium-223. Cancer J (2013) 0.96
Managing the consequences of cancer treatment and the English National Cancer Survivorship Initiative. Acta Oncol (2012) 0.88
The role of MRI in active surveillance of prostate cancer. Curr Opin Urol (2013) 0.87
Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy. Support Care Cancer (2013) 0.81
Salvage of locally recurrent prostate cancer after definitive radiotherapy. Am J Clin Oncol (2014) 0.76